| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Revenue | 191,203 | 195,999 | 442,497 | NaN |
| Cost of revenue (excluding amortization and depreciation) | 14,725 | 12,329 | 35,149 | NaN |
| Research and development expense (reversal) recognized-Solriamfetol | NaN | NaN | 32,094 | NaN |
| Research and development expense recognized-Solriamfetol | 11,231 | 42,106 | NaN | NaN |
| Research and development expense (reversal) recognized-AXS-05 | NaN | NaN | 42,896 | NaN |
| Research and development expense recognized-AXS-05 | 10,904 | 55,312 | NaN | NaN |
| Research and development expense (reversal) recognized-AXS-07 | NaN | NaN | 15,379 | NaN |
| Research and development expense recognized-AXS-07 | 5,470 | 21,421 | NaN | NaN |
| Research and development expense (reversal) recognized-AXS-12 | NaN | NaN | 6,019 | NaN |
| Research and development expense recognized-AXS-12 | 1,488 | 8,482 | NaN | NaN |
| Research and development expense (reversal) recognized-AXS-14 | NaN | NaN | 5,951 | NaN |
| Research and development expense recognized-AXS-14 | 2,696 | 8,485 | NaN | NaN |
| Other research and development | 13,985 | 8,703 | 11,942 | NaN |
| General and administrative expense (excluding share-based compensation expense) | 22,024 | 18,650 | 44,623 | NaN |
| Selling and marketing expense (excluding stock-based compensation expense) | 146,437 | 134,538 | 305,864 | NaN |
| Stock-based compensation expense | 23,438 | 22,730 | 23,103 | NaN |
| Loss in fair value of contingent consideration | 590 | -9,068 | 13,185 | NaN |
| Interest expense, net | -1,185 | -1,172 | -5,385 | NaN |
| Other segment items | 1,572 | 2,037 | 14,193 | NaN |
| Segment net loss | -64,542 | -28,559 | -47,229 | NaN |
| Adjustments and reconciling items | 0 | 0 | 0 | NaN |
| Net loss | -64,542 | -28,559 | -47,229 | -107,386 |
| Stock-based compensation expense | 23,438 | 22,730 | 23,103 | 47,919 |
| Amortization of intangible asset | 1,572 | 1,607 | 1,607 | 3,161 |
| Amortization of debt discount | 159 | 161 | 158 | 984 |
| Gain from lease modification | NaN | 0 | 0 | 2,250 |
| Loss on debt extinguishment | NaN | 0 | 0 | -10,385 |
| Change in operating lease liability | NaN | NaN | -182 | -191 |
| Depreciation | 116 | 114 | 120 | 269 |
| Loss in fair value of contingent consideration | 590 | -9,068 | 13,185 | -6,590 |
| Non-cash lease expense | 844 | 797 | 817 | 1,432 |
| Right-of-use asset amortization for finance lease | 679 | 553 | 684 | 949 |
| Accounts receivable, net | 26,598 | 27,957 | -2,318 | 56,824 |
| Inventories, net | 3,110 | 3,640 | 4,994 | 2,026 |
| Prepaid expenses and other current assets | 9,872 | -6,138 | 3,451 | 4,360 |
| Non-current inventory and other assets | 1,762 | -149 | 1,936 | 3,223 |
| Accounts payable | 41,165 | 11,310 | -37,401 | 19,631 |
| Accrued expenses and other current liabilities | 17,229 | 7,174 | 54,247 | 22,322 |
| Operating lease liability | -608 | -535 | NaN | NaN |
| Net cash used in operating activities | -20,700 | -18,653 | 1,046 | -75,798 |
| Purchases of equipment | 121 | 71 | 58 | 351 |
| Net cash used in investing activities | -121 | -71 | -58 | -351 |
| Proceeds from draw down of debt | 70,000 | 70,000 | 70,000 | 190,000 |
| Payment of debt issuance costs | NaN | 0 | 0 | 3,638 |
| Repayment of debt | 70,000 | 70,000 | 70,000 | 191,988 |
| Payments on principal portion of finance lease obligation | 672 | 541 | 664 | 919 |
| Proceeds from issuance of common stock upon financing | 6,343 | 5,675 | 9,946 | 52,283 |
| Cash paid for common stock issuance costs | 95 | 98 | 189 | 910 |
| Proceeds from issuance of common stock upon exercise of options | 9,981 | 15,338 | 15,524 | 28,696 |
| Payment of contingent consideration | -3,262 | -2,945 | -2,507 | -4,488 |
| Payments of tax withholdings on stock awards | 9,301 | 1,044 | 842 | 5,224 |
| Net cash provided by financing activities | 2,994 | 16,385 | 21,268 | 63,812 |
| Net decrease in cash | -17,827 | -2,339 | 22,256 | -12,337 |
| Cash at beginning of period | 322,933 | 325,272 | 315,353 | NaN |
| Cash at end of period | 305,106 | 322,933 | 325,272 | NaN |
Axsome Therapeutics, Inc. (AXSM)
Axsome Therapeutics, Inc. (AXSM)